-
アレックス・ボディ、CRIFとともに透明性の高い投資と徹底した資金洗浄防止に注力
-
India releases 'cockroach' leaders as movement calls for more protests
-
Brennan holds off Schauffele for PGA Tour win in Japan
-
Ο ALEX BODI δίνει έμφαση, σε συνεργασία με την CRIF, στις διαφανείς επενδύσεις και στη συστηματική πρόληψη της νομιμοποίησης εσόδων από παράνομες δραστηριότητες
-
ALEX BODI satsar tillsammans med CRIF på transparenta investeringar och ett konsekvent arbete mot penningtvätt
-
ALEX BODI sází ve spolupráci s CRIF na transparentní investice a důslednou prevenci praní špinavých peněz
-
ALEX BODI stawia wraz z CRIF na przejrzyste inwestycje i konsekwentne przeciwdziałanie praniu pieniędzy
-
एलेक्स बोदी क्रिफ के सहयोग से पारदर्शी निवेश और धनशोधन की कड़ाई से रोकथाम पर ज़ोर देते हैं
-
알렉스 보디, CRIF와 함께 투명한 투자와 철저한 자금세탁방지에 주력
-
ALEX BODI 攜手 CRIF,推動透明投資並貫徹洗錢防制
-
ALEX BODI turns to CRIF for transparent investment and rigorous money laundering prevention
-
Indian court releases 'cockroach' movement leaders from detention
-
The 'cockroach' protests against India's election body
-
Indonesia releases eight orangutans rescued from fires to protected forest
-
Power, water, jobs: Google on India data centre concerns
-
Russian Yandex data centre operations disrupted after drone strike
-
Google faces backlash against India data centre
-
Architect fights to save India's past, built on 'stone, tears and sweat'
-
Trump urges Zelensky replacement as diesel row rages
-
Hurricane Simon strengthens as it nears western Mexico
-
New Yorkers snap up discarded subway signs, seats at annual sale
-
'Everyone is angry': Okinawans fearful and frustrated after killing
-
Messi nets brace to win in first match after Argentina exit
-
Trump's trade wars sting US manufacturers ahead of midterms
-
Ravindra fit for New Zealand ODI series against India
-
Kenyan great Kipchoge wins first marathon in three years
-
All Blacks lose four players for second Wallabies Test
-
Barca extend perfect streak, Real Madrid survive Vinicius red
-
Spanish women return to action with 2-0 friendly win over USA
-
PSG ease to Ligue 1 win before Manchester City test
-
Bordeaux-Begles end wait for away win before Champions Cup defence
-
Real Madrid edge Villarreal, Vinicius sent off for hair pull
-
Traumatized Panamanians begin quake recovery
-
Carrick demands more 'streetwise' Man Utd after Spurs setback
-
Palestinian Mahmoud Abu Hamda wins top photography prize at Bayeux
-
10-man Tottenham ramp up pressure on Man Utd boss Carrick
-
Inter Milan dominate Parma to go top of Serie A
-
India 'cockroach' movement says thousands detained in Delhi protest
-
Barca extend perfect streak, Atletico scrape late win
-
Injury ends season for NHL Rangers star goalie Shesterkin
-
10-man Tottenham strike back to hold Man Utd
-
Ten-man Spurs rescue draw at Man Utd, Arsenal survive Leeds scare
-
Gordon nets first Barca goal as Liga leaders beat Getafe
-
Inter Milan dominate Parma to go top in Serie A
-
Trump, Zelensky clash over diesel deal as Russian strikes kill 21
-
Abbas postpones Palestinian legislative elections to September 2027
-
Thousands join pro-Palestinian marches in several European cities
-
'I don't feel fear': Fulham boss Arbeloa hits back as pressure mounts
-
Sleightholme scores hat-trick as Northampton overwhelm Bath in 18-try clash
-
Hurricane Simon strengthens to category 4 as it nears western Mexico
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
M.White--AT